gamma-Chaconine



Compound IDCDAMM00860
Common namegamma-Chaconine
IUPAC name2-(hydroxymethyl)-6-[(10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracos-4-en-7-yl)oxy]oxane-3,4,5-triol
Molecular formulaC33H53NO6

Experimental data

Retention time10.06
Adduct[M+K]+
Actual mz598.356
Theoretical mz598.35
Error9.26
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.3189

Identifiers and class information

Inchi keyIDGKMGZVTKHZDA-UHFFFAOYNA-N
SmilesOCC1OC(OC2CC3=CCC4C(CCC5(C)C4CC6N7CC(C)CCC7C(C)C65)C3(C)CC2)C(O)C(O)C1O
SuperclassLipids and lipid-like molecules
ClassSteroids and steroid derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)7
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)559.785
Computed dipole moment(dipole)6.078
Total solvent accessible surface area (SASA)872.086
Hydrophobic component of SASA (FOSA)691.962
Hydrophilic component of SASA (FISA)154.734
Pie component of the SASA (PISA)25.39
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1725.48
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)12.2
Free energy of solvation of dipole (dip^2/V)0.0214072
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0279789
Globularity descriptor (glob)0.797771
Predicted polarizability in cubic angstroms (QPpolrz)58.647
Predicted hexadecane/gas partition coefficient (QPlogPC16)16.335
Predicted octanol/gas partition coefficient (QPlogPoct)32.185
Predicted water/gas partition coefficient (QPlogPw)19.374
Predicted octanol/water partition coefficient (QPlogPo/w)3.084
Predicted aqueous solubility (QPlogS)-5.187
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.613
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.652
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)84.229
Predicted brain/blood partition coefficient (QPlogBB)-1.081
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)37.738
Predicted skin permeability, log Kp (QPlogKp)-5.672
PM3 calculated ionization potential (IP(ev))8.835
PM3 calculated electron affinity (EA(eV))-1.424
Number of likely metabolic reactions (#metab)6
Prediction of binding to human serum albumin (QPlogKhsa)0.541
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)66.507
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)107.192
Number of nitrogen and oxygen atoms (#NandO)7
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q15125EBPAnti-estrogen binding site (AEBS)T25317SEA
P31213SRD5A2Steroid 5-alpha-reductase 2T71390SEA
P08185SERPINA6Corticosteroid binding globulinT88452SEA
Q9UHC9NPC1L1Niemann-Pick C1-like protein 1T33901SEA
Q13133NR1H3LXR-alphaT52297SEA
P11413G6PDGlucose-6-phosphate 1-dehydrogenaseT63484SEA
P05093CYP17A1Cytochrome P450 17A1T89041SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
O15439ABCC4Multidrug resistance protein 4T39919SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T25317DI0366Rheumatoid arthritis[ICD-11: FA20]Q15125EBP
T71390DI0348Prostate hyperplasia[ICD-11: GA90]P31213SRD5A2
T88452DI0037Asthma[ICD-11: CA23]P08185SERPINA6
T88452DI0339Postoperative inflammation[ICD-11: 1A00-CA43]P08185SERPINA6
T88452DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08185SERPINA6
T33901DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]Q9UHC9NPC1L1
T52297DI0117Depression[ICD-11: 6A70-6A7Z]Q13133NR1H3
T63484DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11413G6PD
T89041DI0346Prostate cancer[ICD-11: 2C82]P05093CYP17A1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A

Copyright © 2025